Background
==========

Congenital bicuspid aortic valve (BAV) is the most common type of cardiac malformation, with an estimated prevalence of 1-2% in the general population \[[@B1]\]. BAV, in which two of the three normal aortic cusps are fused together, encompasses a wide spectrum of clinical phenotypes. The valve abnormality may be isolated in some cases, whereas in others the aortic valve abnormality is present in conjunction with other cardiac malformations \[[@B2]\]. BAV may also be associated with varying degrees of aortic valve stenosis and/or insufficiency as well as with aortopathy. Among BAV patients, there is variability in cusp fusion phenotypes. Right coronary and left coronary (R-L) cusp fusion is more common than right coronary and non-coronary (R-NC) cusp fusion. Moreover, R-L cusp fusion is more often associated with additional cardiac malformations, whereas R-NC cusp fusion is more likely to be associated with aortic valve dysfunction \[[@B3]\]. The etiologies of these associations are unknown.

While multiple studies have demonstrated the high heritability of BAV, the underlying genetic causes remain poorly understood \[[@B4]-[@B7]\]. *NOTCH1* and *GATA5* are the only genes that have been linked to bicuspid aortic valve in humans, yet variants in these genes are present in only a minority of individuals with BAV \[[@B8]-[@B14]\]. Mice lacking *Gata5* have partially penetrant BAV of the R-NC subtype, but human studies have not yet demonstrated a specific association between *GATA5* variants and the R-NC subtype of BAV. Animal models of R-L BAV demonstrate excess fusion of the septal and parietal ridges of the outflow tract, whereas R-NC BAVs result from fusion of the septal ridge and posterior intercalated cushions \[[@B15]\]. These studies suggest that these two cusp fusion phenotypes may arise from distinct genetic perturbations in humans.

Despite tremendous advances in gene sequencing technology, the genetic etiology of many common human conditions, including BAV, remains poorly understood. Candidate gene studies have long been used to detect variants in individual genes; such studies are easy to perform but require selection of genes with a proposed role in the disease process of interest. Genome-wide association studies allow investigators to compare multiple individuals with a given condition and identify common variants in a non-candidate driven approach \[[@B16]\]. However, because genome-wide association studies are predicated upon the common disease-common variant hypothesis, this approach is not ideal for the study of rare variants, particularly in complex conditions in which rare variants at multiple loci may be needed to produce a clinically recognizable phenotype \[[@B17],[@B18]\].

Next-generation sequencing (NGS) provides an opportunity for rapid, high-throughput sequencing of entire patient genomes and may overcome the limitation of genome-wide association studies in exploring the role of rare variants in complex diseases \[[@B19]\]. Whole genome sequencing remains at this time a costly technology, thus limiting its application to the sequencing of large cohorts of patients. It also produces a vast amount of data necessitating extensive bioinformatics processing. One option to overcome this issue is the design of targeted capture kits that allow for the rapid and accurate sequencing of only the genetic regions of interest. The two most common approaches to this technique have distinct limitations. Sequencing of a targeted set of genes can be done on individual samples, but this approach is very costly in larger cohorts. Alternatively, sequencing can be performed on pools of individual samples, wherein each sample is labeled with a unique genetic "barcode"; this approach is cost saving, but is quite labor intensive \[[@B20]\]. Combinatorial pooling schemes, wherein individuals are sampled in multiple pools, have been utilized to overcome these pitfalls and still permit identification of the individual sample contributing a given rare variant \[[@B21],[@B22]\].

Here, we present an approach using combinatorial pooling and targeted multi-gene sequencing to study a well-phenotyped cohort of individuals with BAV. We hypothesize that rare variants will be identified amongst a large proportion of the candidate genes, that multiple rare variants will be found in individual probands, and that such variants will segregate by cusp fusion phenotype.

Results
=======

Identification of sequence variants
-----------------------------------

We studied a previously described cohort of 78 patients with echocardiogram-identified BAV \[[@B8]\]. Using a targeted capture approach, we sequenced 97 candidate genes selected by reviewing the literature for genes relevant to heart valve development.

The average depth of coverage for the targeted regions was 268X. Greater than 50X coverage was obtained for 99.04% of the bases sequenced (range: 94.19-99.62), with greater than 100X for 96.11% of bases covered. The percentage of sequencing on target was 71.81%.

Targeted capture identified 42 rare, non-synonymous, exonic variants involving 35 of the candidate genes (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Among these variants, *in-silico* analysis classified 33 of these 42 variants as putative disease-causing changes; Sanger sequencing did not validate two of these 33 variants. The remaining 31 changes were identified in 16 individuals and involved 28 genes (Table [1](#T1){ref-type="table"}). Each variant was identified in only one proband. There were no significant differences in variant burden among BAV fusion phenotypes or isolated BAV versus BAV-CoA, with p = 0.78 and p = 0.77, respectively (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2). Only 2 of these variants (rs72541816 at *APC* and rs116164480 at *GATA5*) were *de novo* changes not present in either parent of the affected probands. These two variants were identified in the same individual with a family history of coarctation of the aorta. Of the 16 individuals in whom putative disease-causing variants were identified, two had variants in genes previously known to be involved in human BAV (*NOTCH1, GATA5*), one of whom we previously described \[[@B8]\]. Four of these 16 individuals had a family history of a left ventricular outflow tract malformation.

###### 

**Rare, non-synonymous, exonic variants in BAV cohort predicted damaging by*in-silico*analysis, confirmed by Sanger sequencing**

   **Gene name**   **Nucleotide change**   **Amino acid change**   **De novo**   **SIFT**   **PP2**   **EA EVS**   **All EVS**   **1000G MAF**   **dbSNP137 ID**
  --------------- ----------------------- ----------------------- ------------- ---------- --------- ------------ ------------- --------------- -----------------
      **APC**            c.C7862G                p.S2621C              yes         0.03      0.641      0.005         0.003          0.058         rs72541816
     **AXIN1**           c.G2522A                 p.R841Q              no          0.4         1        0.012         0.008          0.01          rs34015754
     **AXIN2**           c.C2051T                 p.A684V              no          0.01      0.95       0.002         0.001            0           rs138287857
     **FLT1**            c.C3092G                p.S1031C              no           0          1          0             0              0               N/A
     **GATA4**           c.G1310C                 p.G437A              no           0        0.787        0             0              0               N/A
     **GATA5**            c.T698C                 p.L233P              yes         0.05      0.723      0.001         0.001          0.003         rs116164480
     **GLI1**            c.G3142A                p.D1048N              no           0          1          0             0              0               N/A
     **JAG1**            c.G2810A                 p.R937Q              no          0.47      0.093      0.002         0.001          0.001         rs145895196
     **MCTP2**           c.C1634T                 p.T545M            unknown        0          1          0             0              0               N/A
     **MCTP2**           c.C2539T                 p.L847F              no           0          1        0.0002       0.0002            0           rs150149342
     **MSX1**             c.A581G                 p.K194R              no           0        0.878      0.0003       0.0002            0           rs149092063
    **NFATC1**            c.C230T                 p.P77L               no           0        0.972        0             0              0           rs143045693
    **NFATC1**            c.G628A                 p.V210M              no          0.04        1          0             0              0           rs62096875
     **NOS1**            c.G1975A                 p.A659T              no           0          1          0             0              0               N/A
    **NOTCH1**           c.C6481T                p.P2161S            unknown       0.02      0.975      0.0002       0.0002          0.001         rs201518848
    **NOTCH2**           c.G6363C                p.K2121N              no          0.09      0.964      0.0008       0.0005            0           rs144047610
    **NOTCH3**            c.A509G                 p.H170R              no          0.01      0.974      0.002         0.001          0.001         rs147373451
     **PAX6**            c.G1225A                 p.G409R              no           0          1          0             0              0               N/A
     **PIGF**             c.A370G                 p.T124A              no          0.27      0.711      0.002         0.002          0.001         rs139098189
    **PPP3CA**            c.C334T                 p.R112C              no           0          1          0             0              0               N/A
     **PTCH1**           c.G3487A                p.G1163S              no          0.06        1        0.0006       0.0006          0.001         rs113663584
     **PTCH2**           c.C3139T                p.R1047W              no           0        0.998        0             0              0               N/A
    **SLC35B2**          c.A1105G                 p.I369V              no          0.04      0.891        0          0.00008           0               N/A
     **SNAI3**            c.C488T                 p.T163M              no          0.02      0.752        0             0            0.001         rs202205064
     **SOX9**             c.G817C                 p.V273L              no           0        0.719        0             0              0           rs201477430
     **TBX5**            c.C1115T                 p.S372L              no          0.65      0.861      0.0003       0.0002          0.001         rs143068551
     **TBX5**             c.G787A                 p.V263M              no          0.41      0.995        0           0.004          0.006         rs147405081
     **VEGFB**            c.C286G                 p.Q96E               no           0        0.596      0.002         0.002          0.002         rs111555072
     **VEGFC**            c.A140T                 p.E47V               no          0.01      0.985      0.005         0.004            0           rs55728985
     **WNT4**             c.C129A                 p.C43X               no          STOP      STOP         0             0              0               N/A
    **ZNF236**           c.C4628T                p.P1543L              no          0.03      0.943        0             0              0               N/A

PP2; Polyphen 2.

EA, European American.

EVS, Exome Variant Server.

1000G, 1000 Genomes.

Pathway analysis
----------------

Pathway analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Pathway analysis was used to draw comparisons between the background of only those genes included in the targeted capture and the subset of genes in which rare, non-synonymous exonic variants predicted damaging by *in silico* analysis were identified. The pathway analysis revealed significant enrichment in genes involved in the WNT signaling pathway (p = 0.035).

Pooling design validation
-------------------------

All samples in the cohort underwent Sanger sequencing of the coding regions of *GATA5* as previously reported by our group, used here as a test of the pooling design as well as the sensitivity and specificity of the variant calling algorithm. Four rare variants in *GATA5* (each present in 1/78 individuals) were discovered by Sanger sequencing, of which three were identified by NGS \[[@B8]\]. All of the rare *GATA5* variants identified by our NGS pooling design were attributed to the correct individual as confirmed by Sanger sequencing.

Sanger sequencing of *GATA5* found a variant, p.Q3R, in one individual that was not identified through the pooling design \[[@B8]\]. No pool had this variant above our cut-off threshold of 2.5% (four pools had allele frequencies over 1% with a range of 1.06-1.36%). Coverage of this base was good, with average read depth of 460X.

Discussion
==========

This NGS design utilizing targeted sequencing of pooled BAV patient samples identified 33 rare, non-synonymous exonic variants predicted damaging by *in silico* analysis. Traditional Sanger sequencing methods confirmed 31 of these 33 changes (94%). Analysis of the *GATA5* comparison dataset indicated that the pooling scheme allowed for accurate subject identification. This investigation identified rare variants in 26 genes not previously known to be involved in human BAV; such variants are considered hypothesis-generating and merit further testing in replication cohorts.

Animal models of BAV suggest a possible genotype-phenotype correlation related to cusp fusion phenotypes. However, our data does not support such a correlation in regards to cusp fusion, nor was there a correlation for isolated BAV versus BAV associated with coarctation of the aorta. Sample size and low incidence of familial BAV may limit our ability to detect such an association, but other groups have had similar findings. Rare, non-synonymous exonic variants in *GATA5* have not been shown to correlate with cusp fusion \[[@B8],[@B13]\]. Investigations of familial BAV in large cohorts have demonstrated that cusp fusion morphologies were inherited interchangeably within families \[[@B23],[@B24]\]. Taken together, these studies suggest that differing BAV phenotypes may derive from a common genetic pathway influenced by downstream modifying elements. Thorough testing of genotype-phenotype correlations would require larger cohorts with significant representation of cusp fusion phenotypes, associated congenital cardiac malformations, aortopathy, and aortic valve insufficiency/stenosis.

Prior to this study, only *GATA5* and *NOTCH1* variants had been associated with isolated human BAV. Our data identified variants in 26 additional genes not previously identified in human BAV patients. Interestingly, all of these variants are reported in less than 1% of the Exome Variant Server controls and half are absent in this control population. Nonetheless, only 2 of the 31 putative disease-causing changes confirmed by traditional sequencing methods were *de novo*, in that they were not identified in either parent of the affected proband. We speculate that these 31 variants may be susceptibility alleles, with additional factors (genetic or environmental) required for full phenotype expression \[[@B25]\]. Our finding of multiple variants in the same proband further supports this hypothesis. Among the 16 individuals in whom putative disease-causing variants were identified, the mean variant burden was 1.8 with a range of 1 to 5.

Pathway analysis provides an opportunity to ascribe further meaning to the large number of candidate genes that may be identified in high-throughput approaches such as the one described here. Bioinformatics analysis via DAVID identified significant enrichment of WNT pathway genes including *WNT4*, *PPP3CA*, *NFATC1*, *APC*, *AXIN1* and *AXIN 2*. DAVID pathway analysis can compare a subset of variants to any background of an investigator's choosing; by utilizing a background of only the genes included in the targeted capture as opposed to the whole genome, the pathway analysis is not biased by overrepresentation of WNT pathway genes in the targeted capture design. WNT pathway genes display variable expression at various stages in valvulogenesis and have also been implicated in calcific valvular degeneration \[[@B26],[@B27]\]. Coupling of NGS with pathway analysis allows for the development of more targeted sequencing approaches for subsequent studies. Further investigation into this and similar BAV cohorts could include an enhanced focus on the WNT signaling pathway. A more narrow scope of investigation would then facilitate advanced functional investigations of identified variants.

Several methods are now available for combining multiple individuals into a single sequencing run. Sample-specific indexing uses a short barcode sequence that is unique to each individual in a pool. This barcode is attached to the adapter sequence during library preparation. Commercially available kits now allow up to 96 individuals to be combined in a single run, with deconvolution allowing identification of the individual. Some problems remain in identifying correctly which sequence reads belong to the individual tagged, particularly if single (one end) indexing is used. The pooling method used here does not allow direct deconvolution, but it is not difficult to identify the individual possessing the identified variant. However, the pooling method offers the advantage of error mitigation through use of biological replicates, reducing the false positive rate due to the high frequency of sequencing errors in NGS \[[@B28]\]. Pooling will also overcome problems inherent in the indexing technique itself (including double indexing) that lead to sequencing errors \[[@B29]\].

More precise estimates of the pooling strategy false negative rates and investigation into the causes of these false negatives are necessary to improve the technique. The *GATA5* p.Q3R variant may have been missed for a variety of reasons including, but not limited to: error in DNA concentration measurement of the individual possessing the variant, volume measurement variability during pooling, or stochastic events during sequencing. One potential solution may be utilizing different DNA quantification methods for more accurate concentration prior to pooling. Additionally, a combinatorial design wherein each individual is represented in exactly three rather than two pools would potentially reduce false positive and negative rates.

A cost analysis of our approach showed significant savings. Targeted capture used in conjunction with the pooling scheme herein described resulted in a total sequencing cost of \$15,950 for the entire 78 proband cohort. Targeted capture without pooling would have a total cost of \$54,300 for a cohort of the same sample number, representing a cost savings of \$39,350 from pooling alone. Moreover, assuming a cost of \$1200 per sample for whole exome sequencing, the pooled and targeted approach would produce a relative cost saving of \$77,650 for this cohort as compared to whole exome sequencing without pooling. Compared to whole genome sequencing without pooling (assumed to cost \$5950 per sample), the pooled and targeted technique would realize a savings of \$448,150.

Conclusions
===========

This unique approach to targeted gene sequencing identified a large number of putative disease-causing variants in a cohort of patients with BAV, including variants in 26 genes not previously associated with human BAV. Pathway analysis supported a role for WNT pathway genes in human BAV. The data as a whole further underscore the complex, polygenic nature of BAV. This technique provides a method for sample multiplexing that lowers costs and reduces sequencing errors.

Methods
=======

Study population
----------------

The study cohort, previously described by our group, included 78 unrelated individuals (59 male, 19 female) with BAV \[[@B8]\]. Subjects were prospectively recruited from June 2004 to June 2011 as part of a larger study involving genetic testing in patients with congenital left ventricular tract outflow defects. Informed consent was obtained from study subjects or parents of subjects less than 18 years of age (assent was obtained from subjects 9--17 years of age) under protocols approved by the Institutional Review Board (IRB) at Nationwide Children's Hospital. Subjects with known chromosomal abnormalities were excluded from the analysis. The majority of individuals were of Caucasian ethnicity, with 1 African-American, 1 Asian, and 3 Hispanic individuals. Each subject had undergone clinical echocardiography with images sufficient to identify associated cardiac malformations and aortic valve cusp fusion morphology (Table [2](#T2){ref-type="table"}). Fifty of the 78 subjects (64%) had isolated BAV while the remainder had BAV-CoA. Forty-six subjects (59%) had R-L cusp fusion, 39% had R-NC fusion, and 2% had L-NC fusion. Eighteen of the 78 subjects had a family history of a left ventricular outflow tract defect. For the majority of subjects, parent samples were also obtained under the same IRB protocol. Genomic DNA was isolated from blood or saliva samples using the 5 PRIME DNA extraction kit (Thermo Fisher Scientific, Pittsburgh, PA).

###### 

Cardiac phenotype of study population

                  **BAV**    **BAV-CoA**   **Overall**
  ------------- ----------- ------------- -------------
  **R-L**        27(34.5%)    20(25.5%)      47(60%)
  **R-NC**        22(28%)       7(9%)       30(38.5%)
  **L-NC**         1(1%)        1(1%)        2(2.5%)
  **Overall**     50(64%)      28(36%)           

BAV, bicuspid aortic valve (isolated).

BAV-CoA, bicuspid aortic valve with coarctation of the aorta.

R-L, fusion of right coronary cusp and left coronary cusp.

R-NC, fusion of right coronary cusp and non-coronary cusp.

L-NC, fusion of left coronary cusp and non-coronary cusp.

Pooling scheme
--------------

Proband genomic DNA was combined into 19 unique pools each representing 9 or 10 individuals. The pools were constructed using overlapping design such that each individual was represented in exactly two pools, and a given rare variant could be uniquely attributed to a single individual on the basis of which two pools contained the variant. Individual genomic DNA samples were quantified by Nanodrop (Thermo Fisher Scientific), diluted to a concentration of 200 ng/microliter, and then requantified by Qubit fluorometer (Invitrogen Life Technologies, Carlsbad, CA). Quality of the DNA was assessed by SYBR Gold agarose gel (Life Technologies). Samples were then pooled, with the total amount of DNA for each pool consisting of 5 micrograms in 50 microliters (i.e. 500 ng per sample for a pool of 10 individuals and 550 ng per sample for a pool of 9 individuals).

Targeted capture
----------------

A custom, targeted gene capture was designed using the Agilent SureSelect Target Enrichment kit (Table [3](#T3){ref-type="table"}). Candidate genes were selected on the basis of relevance to cardiac development and/or congenital heart defects in humans and animal models. Reference sequences were obtained from the Ensembl database. Probes were designed using paired, double-end, 75 base pair reads with centered design and 2x tiling frequency. A total of 97 candidate genes were probed using a whole gene interval approach, representing 7.6 Mb of DNA. Analysis was subsequently confined to exonic regions.

###### 

Targeted capture gene list

  **Ensembl gene ID**   **Gene name**   **Chromosome**   **Gene start (bp)**   **Gene end (bp)**   **Size**
  --------------------- --------------- ---------------- --------------------- ------------------- ----------
  **ENSG00000107796**   ACTA2           10               90694831              90751147            56316
  **ENSG00000115170**   ACVR1           2                158592958             158732374           139416
  **ENSG00000134982**   APC             5                112043195             112181936           138741
  **ENSG00000081181**   ARG2            14               68086515              68118437            31922
  **ENSG00000103126**   AXIN1           16               337440                402673              65233
  **ENSG00000168646**   AXIN2           17               63524681              63557765            33084
  **ENSG00000149541**   B3GAT3          11               62382768              62389647            6879
  **ENSG00000242252**   BGLAP           1                156211753             156213112           1359
  **ENSG00000125845**   BMP2            20               6748311               6760910             12599
  **ENSG00000125378**   BMP4            14               54416454              54425479            9025
  **ENSG00000107779**   BMPR1A          10               88516396              88684945            168549
  **ENSG00000138696**   BMPR1B          4                95679119              96079599            400480
  **ENSG00000204217**   BMPR2           2                203241659             203432474           190815
  **ENSG00000134072**   CAMK1           3                9799026               9811676             12650
  **ENSG00000105974**   CAV1            7                116164839             116201233           36394
  **ENSG00000179776**   CDH5            16               66400533              66438686            38153
  **ENSG00000132535**   DLG4            17               7093209               7123369             30160
  **ENSG00000198719**   DLL1            6                170591294             170599561           8267
  **ENSG00000090932**   DLL3            19               39989557              39999118            9561
  **ENSG00000128917**   DLL4            15               41221538              41231237            9699
  **ENSG00000106991**   ENG             9                130577291             130617035           39744
  **ENSG00000138685**   FGF2            4                123747863             123819391           71528
  **ENSG00000107831**   FGF8            10               103530081             103535827           5746
  **ENSG00000102755**   FLT1            13               28874489              29069265            194776
  **ENSG00000136574**   GATA4           8                11534468              11617511            83043
  **ENSG00000130700**   GATA5           20               61038553              61051026            12473
  **ENSG00000141448**   GATA6           18               19749404              19782491            33087
  **ENSG00000111087**   GLI1            12               57853918              57866045            12127
  **ENSG00000074047**   GLI2            2                121493199             121750229           257030
  **ENSG00000106571**   GLI3            7                42000548              42277469            276921
  **ENSG00000105464**   GRIN2D          19               48898132              48948187            50055
  **ENSG00000164116**   GUCY1A3         4                156587863             156653501           65638
  **ENSG00000061918**   GUCY1B3         4                156680144             156728743           48599
  **ENSG00000164683**   HEY1            8                80676245              80680098            3853
  **ENSG00000135547**   HEY2            6                126068810             126082415           13605
  **ENSG00000163909**   HEYL            1                40089825              40105617            15792
  **ENSG00000080824**   HSP90AA1        14               102547106             102606036           58930
  **ENSG00000096384**   HSP90AB1        6                44214824              44221620            6796
  **ENSG00000166598**   HSP90B1         12               104323885             104347423           23538
  **ENSG00000101384**   JAG1            20               10618332              10654608            36276
  **ENSG00000184916**   JAG2            14               105607318             105635161           27843
  **ENSG00000123700**   KCNJ2           17               68164814              68176160            11346
  **ENSG00000127528**   KLF2            19               16435651              16438337            2686
  **ENSG00000140563**   MCTP2           15               94774767              95023632            248865
  **ENSG00000087245**   MMP2            16               55423612              55540603            116991
  **ENSG00000163132**   MSX1            4                4861393               4865663             4270
  **ENSG00000120149**   MSX2            5                174151536             174158144           6608
  **ENSG00000131196**   NFATC1          18               77155772              77289325            133553
  **ENSG00000183072**   NKX2-5          5                172659112             172662360           3248
  **ENSG00000089250**   NOS1            12               117645947             117889975           244028
  **ENSG00000007171**   NOS2            17               26083792              26127525            43733
  **ENSG00000164867**   NOS3            7                150688083             150711676           23593
  **ENSG00000148400**   NOTCH1          9                139388896             139440314           51418
  **ENSG00000134250**   NOTCH2          1                120454176             120612240           158064
  **ENSG00000074181**   NOTCH3          19               15270445              15311792            41347
  **ENSG00000204301**   NOTCH4          6                32162620              32191844            29224
  **ENSG00000151665**   PIGF            2                46808076              46844258            36182
  **ENSG00000076356**   PLXNA2          1                208195587             208417665           222078
  **ENSG00000132170**   PPARG           3                12328867              12475855            146988
  **ENSG00000138814**   PPP3CA          4                101944566             102269435           324869
  **ENSG00000188191**   PRKAR1B         7                588834                767287              178453
  **ENSG00000154229**   PRKCA           17               64298754              64806861            508107
  **ENSG00000080815**   PSEN1           14               73603126              73690399            87273
  **ENSG00000143801**   PSEN2           1                227057885             227083806           25921
  **ENSG00000185920**   PTCH1           9                98205262              98279339            74077
  **ENSG00000117425**   PTCH2           1                45285516              45308735            23219
  **ENSG00000131759**   RARA            17               38465444              38513094            47650
  **ENSG00000077092**   RARB            3                25215823              25639423            423600
  **ENSG00000172819**   RARG            12               53604354              53626764            22410
  **ENSG00000124813**   RUNX2           6                45295894              45632086            336192
  **ENSG00000186350**   RXRA            9                137208944             137332431           123487
  **ENSG00000204231**   RXRB            6                33161365              33168630            7265
  **ENSG00000143171**   RXRG            1                165370159             165414433           44274
  **ENSG00000162572**   SCNN1D          1                1214447               1227409             12962
  **ENSG00000075223**   SEMA3C          7                80371854              80551675            179821
  **ENSG00000164690**   SHH             7                155592680             155604967           12287
  **ENSG00000128602**   SMO             7                128828713             128853386           24673
  **ENSG00000124216**   SNAI1           20               48599536              48605423            5887
  **ENSG00000019549**   SNAI2           8                49830249              49834299            4050
  **ENSG00000185669**   SNAI3           16               88744090              88752901            8811
  **ENSG00000125398**   SOX9            17               70117161              70122561            5400
  **ENSG00000184058**   TBX1            22               19744226              19771116            26890
  **ENSG00000121068**   TBX2            17               59477257              59486827            9570
  **ENSG00000164532**   TBX20           7                35242042              35293758            51716
  **ENSG00000089225**   TBX5            12               114791736             114846247           54511
  **ENSG00000105329**   TGFB1           19               41836813              41859831            23018
  **ENSG00000106799**   TGFBR1          9                101866320             101916474           50154
  **ENSG00000163513**   TGFBR2          3                30647994              30735634            87640
  **ENSG00000122691**   TWIST1          7                19060614              19157295            96681
  **ENSG00000070010**   UFD1L           22               19437464              19466738            29274
  **ENSG00000112715**   VEGFA           6                43737921              43754224            16303
  **ENSG00000173511**   VEGFB           11               64002010              64006259            4249
  **ENSG00000150630**   VEGFC           4                177604689             177713881           109192
  **ENSG00000105989**   WNT2            7                116916685             116963343           46658
  **ENSG00000162552**   WNT4            1                22446461              22470462            24001
  **ENSG00000184937**   WT1             11               32409321              32457176            47855
  **ENSG00000130856**   ZNF236          18               74534563              74682683            148120
                                                                               CAPTURE SIZE        7567444

Sequencing
----------

Sequencing of the pooled target captured proband genomic DNA was performed on the Illumina HiSeq 2000. Variants considered potentially pathogenic identified by NGS were subsequently confirmed by Sanger sequencing. Where available, parent samples were also sequenced for these potentially pathogenic variants. Sequencing primers are available upon request.

Bioinformatics algorithms
-------------------------

Bioinformatics analysis was performed using Churchill, our laboratory's pipeline for the discovery of human genetic variation. Churchill utilizes the Burrows Wheeler Aligner (BWA) for the alignment of sequence data to the reference genome, hg19. Further refinement steps were performed on the aligned sequence data using Genome Analysis ToolKit (GATK) following the Broad Institute's guidelines for best practices (<https://www.broadinstitute.org/gatk/guide/best-practices>). We utilized the GATK's (version 2.4-9) UnifiedGenotyper (UG) to call variants in the pooled samples. In order to properly handle the pooled data, we amended the recommended UG settings by including the --sample_ploidy configuration parameter and giving it a value of 20, reflecting the potential for 20 individual alleles in a pooled sample of 10 individuals. The threshold for calling was set to 2.5% alternate allele frequency on the basis of the pooling scheme.

In-silico analysis
------------------

Rare, non-synonymous, exonic variants were analyzed using the Polyphen 2 and SIFT algorithms. Reference populations from the 1000 Genomes Project and Exome Variant Server were utilized as control populations \[[@B30],[@B31]\]. Pathway analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) with cutoffs of p-value less than 0.05 \[[@B32],[@B33]\].

Availability of supporting data
-------------------------------

This project has been registered with the National Center for Biotechnology Information (NCBI) BioProject database, identifier PRJNA260036, and can be accessed at: <http://www.ncbi.nlm.nih.gov/bioproject/260036>.

Supporting sequence data for this project has been deposited with the NCBI Sequence Read Archive. The study accession is SRP045998, available at the following link: <http://www.ncbi.nlm.nih.gov/sra/?term=SRP045998> Biosample IDs for the pools, with their corresponding URLs are:

3015266: <http://www.ncbi.nlm.nih.gov/biosample/3015266>

3015267: <http://www.ncbi.nlm.nih.gov/biosample/3015267>

3015268: <http://www.ncbi.nlm.nih.gov/biosample/3015268>

3015269: <http://www.ncbi.nlm.nih.gov/biosample/3015269>

3015270: <http://www.ncbi.nlm.nih.gov/biosample/3015270>

3015271: <http://www.ncbi.nlm.nih.gov/biosample/3015271>

3015272: <http://www.ncbi.nlm.nih.gov/biosample/3015272>

3015273: <http://www.ncbi.nlm.nih.gov/biosample/3015273>

3015274: <http://www.ncbi.nlm.nih.gov/biosample/3015274>

3015275: <http://www.ncbi.nlm.nih.gov/biosample/3015275>

3015276: <http://www.ncbi.nlm.nih.gov/biosample/3015276>

3015277: <http://www.ncbi.nlm.nih.gov/biosample/3015277>

3015278: <http://www.ncbi.nlm.nih.gov/biosample/3015278>

3015279: <http://www.ncbi.nlm.nih.gov/biosample/3015279>

3015280: <http://www.ncbi.nlm.nih.gov/biosample/3015280>

3015281: <http://www.ncbi.nlm.nih.gov/biosample/3015281>

3015282: <http://www.ncbi.nlm.nih.gov/biosample/3015282>

3015283: <http://www.ncbi.nlm.nih.gov/biosample/3015283>

3015284: <http://www.ncbi.nlm.nih.gov/biosample/3015284>

3015285: <http://www.ncbi.nlm.nih.gov/biosample/3015285>
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